Various alphabetized medical records
Industries

Life Sciences Commercial Disputes

New product introductions in the life sciences sector are frequently complex, costly, and time-consuming undertakings, and collaborations between companies are common. Disputes may arise at all stages of development and commercialization. Our expertise helps clients navigate litigated and arbitrated disputes involving drug development and commercialization and analyze relevant commercial factors (size of the opportunity, therapeutic area, business risks, etc.). CRA has provided expert reports and testimony evaluating development and commercialization efforts and assessing damages associated with alleged contractual breaches and other commercial issues.

Our focus areas

Engagements

  • 01
    Milestone payments in funding agreement for a cystic fibrosis therapy
    CRA was retained by a non-profit organization to provide an expert opinion on damages in a breach of contract arbitration concerning a funding agreement...
    View engagement
  • 02
    Impact of channel stuffing of an antiviral product
    In a Canadian dispute for an antiviral product, CRA was retained to evaluate lost unit sales and lost profits suffered by a branded company from the allegedly...
    View engagement
  • 03
    CRA addressed a claim that a company had improperly failed to pay required development milestones upon termination of a drug development program
    In litigation before the Delaware Court of Chancery, a CRA expert was asked to address the basis for a company’s decision to terminate the development of a...
    View engagement

Subscribe to recieve our latest Insights.

Subscribe